Tag:
Halozyme
Latest Headlines
Latest Headlines
Halozyme shares plunge on FDA rejection
Shares of Halozyme Therapeutics plunged more than 20% this morning after the news spread that the FDA wants to see more data on its HyQ Biologics before it can formally decide on its fate.
Halozyme scores $63M drug delivery deal
Halozyme has inked another pact for rHuPH20, an enzyme designed to spur the absorption of certain injectables. This $63 million deal--$9 million upfront and $54 million in milestones--gives Intrexon
Halozyme, Baxter to pitch FDA on Hylenex fixes
Halozyme Therapeutics has identified a corrective action plan to get its Hylenex pediatric-rehydration product back on the market. It completed a manufacturing root cause investigation and is
Recall threatens Baxter/Halozyme deal
Stability testing has uncovered particle contamination in Halozyme's Hylenex recombinant, a fluid absorption drug, leading to a voluntary recall of all lots, some 3,500 vials in total. The
Halozyme shares slide on osteoporosis program failure
Halozyme Therapeutics is dumping an early-stage osteoporosis program after witnessing severe site injection reactions. Investors--in no mood for setbacks, no matter how early in the development
ALSO NOTED: Halozyme inks tech pact; Bioniche gains SPA; Ariad shares on rise; and much more...
> Halozyme Therapeutics has agreed to put its technology to work to develop a new formulation of Baxter's Gammagard Liquid for subcutaneous delivery. Gammagard is used to treat primary
C&L: Hedegaard takes helm at Bavarian Nordic
Bavarian Nordic said Anders Hedegaard will assume the position of president and CEO of the group on August 1. Peter Wulff will transfer to the position of executive vice president of business
DEALS: GSK, Epix ink $1.2B deal
GSK, Epix ink $1.2B deal
Roche and Xenon ink pact on anemia therapies
Roche Holdings has agreed to a deal with Xenon to develop new anemia therapies. Roche will invest $7 million and pay up to $44 million in milestones for the first product. Roche gains an option to commercialize protein therapeutics targeting hemojuvelin as well as a licensing option for small molecule inhibitors of HJV.
- read the AFX report on the deal
Related …
Halozyme shares soar on major licensing pact
News that Roche has licensed Halozyme Therapeutics' drug delivery technology--Enhanze--in a deal worth up to $581 million sent Halozyme's stock up a whopping 60 percent. Halozyme gains $20 million up front for Roche's use of the technology for three specific drug targets and has an option to commercialize the technology on another 10 therapies over 10 years. Milestone payments on the first three programs could be worth up to $111 million with another $47 million on each of the next 10 …
